Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,346,656
  • Shares Outstanding, K 352,704
  • Annual Sales, $ 8,380 M
  • Annual Income, $ -4,148,000 K
  • 60-Month Beta 1.02
  • Price/Sales 1.08
  • Price/Cash Flow 2.52
  • Price/Book 8.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.93
  • Number of Estimates 6
  • High Estimate 1.04
  • Low Estimate 0.88
  • Prior Year 1.03
  • Growth Rate Est. (year over year) -9.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.16 +5.33%
on 02/19/20
30.15 -12.11%
on 01/22/20
-3.23 (-10.86%)
since 01/21/20
3-Month
25.16 +5.33%
on 02/19/20
31.97 -17.11%
on 12/13/19
-1.25 (-4.50%)
since 11/21/19
52-Week
18.72 +41.56%
on 10/07/19
31.97 -17.11%
on 12/13/19
+2.99 (+12.72%)
since 02/21/19

Most Recent Stories

More News
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat

Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.

PFE : 35.72 (-0.36%)
AGN : 200.15 (+0.71%)
AERI : 21.59 (+8.55%)
BHC : 26.50 (+0.34%)
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss

Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.

UTHR : 106.96 (-0.43%)
PCRX : 48.49 (-3.06%)
XNCR : 35.17 (-2.60%)
BHC : 26.50 (+0.34%)
Should You Buy Bausch Health (BHC) Ahead of Earnings?

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BHC : 26.50 (+0.34%)
Should Value Investors Pick Bausch Health (BHC) Stock Now?

Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.

BHC : 26.50 (+0.34%)
Aerie's (AERI) Application for Roclanda Accepted in Europe

European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.

AGN : 200.15 (+0.71%)
PFE : 35.72 (-0.36%)
AERI : 21.59 (+8.55%)
BHC : 26.50 (+0.34%)
5 Reasons Why Ironwood Stock Should Be in Your Portfolio

We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.

AZN : 50.17 (+2.51%)
AGN : 200.15 (+0.71%)
IRWD : 11.63 (-3.16%)
BHC : 26.50 (+0.34%)
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris

Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.

ALKS : 20.24 (-0.93%)
INVA : 15.12 (+0.13%)
ANIK : 42.75 (+1.79%)
BHC : 26.50 (+0.34%)
Top Ranked Value Stocks to Buy for December 13

Top Ranked Value Stocks to Buy for December 13

ODP : 2.55 (-4.85%)
NMM : 10.99 (-1.79%)
BHC : 26.50 (+0.34%)
AEL : 32.41 (-2.76%)
Are You Looking for a Top Momentum Pick? Why Bausch Health (BHC) is a Great Choice

Does Bausch Health (BHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

BHC : 26.50 (+0.34%)
Is Bausch Health (BHC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 26.50 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade BHC with:

Business Summary

Bausch Health Companies Inc. develops and distributes drugs. It develops drugs for unmet medical needs in central nervous system disorders and distributes generic and branded generic drugs primarily in Latin America and Eastern Europe. Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 26.91
1st Resistance Point 26.70
Last Price 26.50
1st Support Level 26.11
2nd Support Level 25.73

See More

52-Week High 31.97
Fibonacci 61.8% 26.91
Last Price 26.50
Fibonacci 50% 25.34
Fibonacci 38.2% 23.78
52-Week Low 18.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar